MESO Nasdaq update, page-5601

Have a look at the jump in valuation from piper sandler this week - $US4 to $US11 for MESO - that shows the leverage. As products get closer to approval and uncertainty is removed the share price should move towards valuation levels. That could happen before the final approval, particularly if uncertainties regarding funding and FDA approvals were removed. It is within SI's power to remove at least some of these uncertainties and that should result in a higher share price...but will he do it?The average analyst price target is $US16, but most of the potential products are heavily discounted due to the high uncertainty. If SI were to clear up some of this uncertainty, those valuations would rise even further. Valuations for all other products should rise as we get more certainty on approval for the first product. A CR, done properly, should only cost the share price 2-2.5%. They could've already done a 1:10 at around $A1.00 when the price jumped over $A1.30 on BLA acceptance. TERP $A1.27. Easy.GG should underwrite it and go as high as 25% ownership if necessary. That would raise enough money to get through to mid 2025, including funding the back pain trial. The price moves much more than 2.5% in a day recently - so it would not be a big deal and would remove a lot of uncertainty.There's the possibility that FDA approval happens in less than 6 months and that new partners then jump in with big upfront payments of over $US100m. If so, a CR may not be needed. Only SI knows.

Another opinion.

Aloha.